Sweet syndrome as terminal event in ruxolitinib-treated myelofibrosis.
Sweet syndrome as terminal event in ruxolitinib-treated myelofibrosis.
复制标题
DOI：
10.1111/bjh.13334
复制
发表时间：
2015-05-01
影响因子：
6.5
通讯作者：
Saja, Khalid
中科院分区：
文献类型：
--
作者：
Chatterjee, Basabi;Rqieh, Usama;Saja, Khalid
本文报告一例77岁女性原发性血小板增多症后骨髓纤维化入院治疗，病情恶化。她曾服用鲁索利替尼治疗症状性脾肿大和与骨髓纤维化相关的体质症状。她还接受了可能是皮肤感染的抗菌药治疗，并讨论了甜蜜综合征，这是一种罕见的反应性皮肤疾病，以白细胞增多和疼痛的皮肤损害为特征。
The article presents a case study of a 77-year-old woman with post-essential thrombocythaemia myelofibrosis was admitted to hospital with general deterioration. She had taking ruxolitinib for management of symptomatic splenomegaly and constitutional symptoms related to myelofibrosis. She was also treated with antimicrobials for presumed skin infection and discusses the sweet syndrome, a rare reactive skin condition characterized by leucocytosis and painful skin lesions.